nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acknowledgements, Committees, Sponsors and Supporters
|
|
|
|
22 |
S4 |
p. iv5 |
artikel |
2 |
agenda and abstracts of satellite symposia
|
|
|
|
22 |
S4 |
p. iv244-iv257 |
artikel |
3 |
Aggressive lymphoma
|
|
|
|
22 |
S4 |
p. iv190-iv197 |
artikel |
4 |
Apoptosis: from biology to therapeutic targeting*
|
O'Connor, O.A. |
|
|
22 |
S4 |
p. iv76-iv79 |
artikel |
5 |
Author index
|
|
|
|
22 |
S4 |
p. iv258-iv269 |
artikel |
6 |
Autologous transplant
|
|
|
|
22 |
S4 |
p. iv168-iv170 |
artikel |
7 |
Biology
|
|
|
|
22 |
S4 |
p. iv143-iv147 |
artikel |
8 |
CLL
|
|
|
|
22 |
S4 |
p. iv171-iv174 |
artikel |
9 |
CLL / myeloma
|
|
|
|
22 |
S4 |
p. iv242-iv243 |
artikel |
10 |
Conference schedule
|
|
|
|
22 |
S4 |
p. iv10-iv24 |
artikel |
11 |
Controversy I: Controversies in follicular lymphomas
|
|
|
|
22 |
S4 |
p. iv81-iv82 |
artikel |
12 |
Controversy II: is interim PET useful in planning treatment for DLBCL?
|
|
|
|
22 |
S4 |
p. iv130 |
artikel |
13 |
disclosures
|
|
|
|
22 |
S4 |
p. iv275-iv281 |
artikel |
14 |
DLBCL
|
|
|
|
22 |
S4 |
p. iv223-iv230 |
artikel |
15 |
Editorial Board
|
|
|
|
22 |
S4 |
p. ii-iii |
artikel |
16 |
Educational and Abstract Book of the 11th International conference on Malignant Lymphoma
|
|
|
|
22 |
S4 |
p. iv6 |
artikel |
17 |
Educational book - list of Meet the Professor articels
|
|
|
|
22 |
S4 |
p. iv25 |
artikel |
18 |
Epidemiology
|
|
|
|
22 |
S4 |
p. iv141-iv142 |
artikel |
19 |
Epidemiology and risk factors
|
|
|
|
22 |
S4 |
p. iv203-iv205 |
artikel |
20 |
“Focus on…” Session: allogeneic transplantation
|
|
|
|
22 |
S4 |
p. iv94-iv95 |
artikel |
21 |
“Focus on…” session: high-dose chemotherapy
|
|
|
|
22 |
S4 |
p. iv115-iv116 |
artikel |
22 |
“Focus on…” Session: immunodeficiency and lymphoma
|
|
|
|
22 |
S4 |
p. iv98-iv99 |
artikel |
23 |
“Focus on…” session: lymphoma in the elderly
|
|
|
|
22 |
S4 |
p. iv117-iv118 |
artikel |
24 |
“Focus on…” session: monoclonal antibodies
|
|
|
|
22 |
S4 |
p. iv131-iv132 |
artikel |
25 |
“Focus on…” session: new drug combinations
|
|
|
|
22 |
S4 |
p. iv119-iv120 |
artikel |
26 |
“Focus on…” Session: PET use in lymphoma
|
|
|
|
22 |
S4 |
p. iv96-iv97 |
artikel |
27 |
“Focus on…” session: plasma cell disorders and Waldenström macroglobulinemia
|
|
|
|
22 |
S4 |
p. iv121-iv122 |
artikel |
28 |
“Focus on…” Session: primary CNS lymphoma
|
|
|
|
22 |
S4 |
p. iv92-iv93 |
artikel |
29 |
“Focus on…” session: primary mediastinal BCL
|
|
|
|
22 |
S4 |
p. iv133-iv134 |
artikel |
30 |
“Focus on…” Session: radiotherapy and early stage
|
|
|
|
22 |
S4 |
p. iv90-iv91 |
artikel |
31 |
“Focus on…” Session: update of randomised trials
|
|
|
|
22 |
S4 |
p. iv88-iv89 |
artikel |
32 |
Genomics
|
|
|
|
22 |
S4 |
p. iv148-iv152 |
artikel |
33 |
Hodgkin lymphoma
|
|
|
|
22 |
S4 |
p. iv238-iv239 |
artikel |
34 |
Hodgkin lymphoma
|
|
|
|
22 |
S4 |
p. iv179-iv182 |
artikel |
35 |
I. Epidemiology of adult non-Hodgkin lymphoma
|
Boffetta, P. |
|
|
22 |
S4 |
p. iv27-iv31 |
artikel |
36 |
III. Role of allotransplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia
|
Dreger, P. |
|
|
22 |
S4 |
p. iv36-iv39 |
artikel |
37 |
II. New perspectives and challenges in the understanding of mantle cell lymphoma
|
Navarro, A. |
|
|
22 |
S4 |
p. iv32-iv35 |
artikel |
38 |
Imaging
|
|
|
|
22 |
S4 |
p. iv215-iv216 |
artikel |
39 |
Immunodeficiency lymphoma
|
|
|
|
22 |
S4 |
p. iv235-iv237 |
artikel |
40 |
Indolent lymphoma
|
|
|
|
22 |
S4 |
p. iv183-iv189 |
artikel |
41 |
Indolent NHL
|
|
|
|
22 |
S4 |
p. iv217-iv219 |
artikel |
42 |
IV. Epigenetics: what it is and what it can bring
|
Esteller, M. |
|
|
22 |
S4 |
p. iv40 |
artikel |
43 |
IX. Chronic lymphocytic leukemia for the clinician
|
Hallek, M. |
|
|
22 |
S4 |
p. iv54-iv56 |
artikel |
44 |
Key note lectures
|
|
|
|
22 |
S4 |
p. iv80 |
artikel |
45 |
Lymphoma biology
|
|
|
|
22 |
S4 |
p. iv206-iv210 |
artikel |
46 |
Mantle cell lymphoma
|
|
|
|
22 |
S4 |
p. iv220-iv222 |
artikel |
47 |
Mantle cell lymphoma
|
|
|
|
22 |
S4 |
p. iv161-iv163 |
artikel |
48 |
New drugs
|
|
|
|
22 |
S4 |
p. iv198-iv202 |
artikel |
49 |
New drugs and mechanism
|
|
|
|
22 |
S4 |
p. iv240-iv241 |
artikel |
50 |
Pathology and clinico-pathological correlations
|
|
|
|
22 |
S4 |
p. iv153-iv156 |
artikel |
51 |
Pathology and clinico-pathological correlations
|
|
|
|
22 |
S4 |
p. iv211-iv214 |
artikel |
52 |
Pediatric lymphoma
|
|
|
|
22 |
S4 |
p. iv175-iv178 |
artikel |
53 |
PET
|
|
|
|
22 |
S4 |
p. iv157-iv160 |
artikel |
54 |
Satellite symposia schedule
|
|
|
|
22 |
S4 |
p. iv9 |
artikel |
55 |
Session 7: aggressive lymphoma
|
|
|
|
22 |
S4 |
p. iv106-iv107 |
artikel |
56 |
Session 10: CLL
|
|
|
|
22 |
S4 |
p. iv123-iv124 |
artikel |
57 |
Session 15: Hodgkin lymphoma
|
|
|
|
22 |
S4 |
p. iv138-iv140 |
artikel |
58 |
Session 13: indolent lymphoma
|
|
|
|
22 |
S4 |
p. iv128-iv129 |
artikel |
59 |
Session 12: lymphoma and apoptosis
|
|
|
|
22 |
S4 |
p. iv127 |
artikel |
60 |
Session 2: Lymphoma and its microenvironment
|
|
|
|
22 |
S4 |
p. iv84-iv85 |
artikel |
61 |
Session 5: lymphoma and the immune system
|
|
|
|
22 |
S4 |
p. iv102-iv103 |
artikel |
62 |
Session 1: Lymphoma epidemiology
|
|
|
|
22 |
S4 |
p. iv83 |
artikel |
63 |
Session 4: lymphoma genomics
|
|
|
|
22 |
S4 |
p. iv100-iv101 |
artikel |
64 |
Session 3: Mantle cell lymphoma
|
|
|
|
22 |
S4 |
p. iv86-iv87 |
artikel |
65 |
Session 8: pathology and clinicopathological correlations
|
|
|
|
22 |
S4 |
p. iv108-iv111 |
artikel |
66 |
Session 9: pediatric lymphoma
|
|
|
|
22 |
S4 |
p. iv112-iv114 |
artikel |
67 |
Session 14: signalling pathways in lymphoma
|
|
|
|
22 |
S4 |
p. iv135-iv137 |
artikel |
68 |
Session 6: targeting the lymphoma cell surface
|
|
|
|
22 |
S4 |
p. iv104-iv105 |
artikel |
69 |
Session 11: T-cell lymphomas
|
|
|
|
22 |
S4 |
p. iv125-iv126 |
artikel |
70 |
Stem cell transplant
|
|
|
|
22 |
S4 |
p. iv232-iv234 |
artikel |
71 |
Subject index
|
|
|
|
22 |
S4 |
p. iv270-iv274 |
artikel |
72 |
Summary of the conference schedule
|
|
|
|
22 |
S4 |
p. iv7-iv8 |
artikel |
73 |
Table of Contents
|
|
|
|
22 |
S4 |
p. iv-v |
artikel |
74 |
T-cell lymphoma
|
|
|
|
22 |
S4 |
p. iv164-iv167 |
artikel |
75 |
T-cell lymphoma
|
|
|
|
22 |
S4 |
p. iv231 |
artikel |
76 |
VI. DNA microarray technology. Principles and application to the analysis of malignant tumours (with special emphasis on lymphoma)
|
Fey, M.F. |
|
|
22 |
S4 |
p. iv44-iv46 |
artikel |
77 |
VIII. Radioimmunotherapy in malignant lymphoma: an underused tool?
|
Hagenbeek, A. |
|
|
22 |
S4 |
p. iv51-iv53 |
artikel |
78 |
VII. The role of the microenvironment in lymphoid cancers
|
Gascoyne, R.D. |
|
|
22 |
S4 |
p. iv47-iv50 |
artikel |
79 |
V. Primary CNS lymphoma in immunocompetent patients
|
Marturano, E. |
|
|
22 |
S4 |
p. iv41-iv43 |
artikel |
80 |
XI. Distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma
|
Jack, A. |
|
|
22 |
S4 |
p. iv61-iv63 |
artikel |
81 |
XII. Gray zone lymphomas: a biological experiment, and a challenge for diagnosis and management
|
Eberle, Franziska C. |
|
|
22 |
S4 |
p. iv64-iv66 |
artikel |
82 |
XIII. The role of immunotherapy in the treatment of lymphoma
|
Levy, R. |
|
|
22 |
S4 |
p. iv67 |
artikel |
83 |
XIV. T- and NK-cell lymphoproliferative disorders
|
Rosen, S. |
|
|
22 |
S4 |
p. iv68-iv71 |
artikel |
84 |
XV. Primary cutaneous lymphomas
|
Willemze, R. |
|
|
22 |
S4 |
p. iv72-iv75 |
artikel |
85 |
X. When should radiotherapy be used in lymphoma?
|
Illidge, T. |
|
|
22 |
S4 |
p. iv57-iv60 |
artikel |